emphasis is mine.....
Wednesday June 14, 12:13 pm Eastern Time
Company Press Release
SOURCE: MorphoSys AG and Eos Biotechnology, Inc.
MorphoSys Licenses Human Antibody Library
Technology to Eos Biotechnology
MUNICH, Germany and SOUTH SAN FRANCISCO, Calif., June 14 /PRNewswire/ --
MorphoSys AG, a Munich-based biotechnology company, and Eos Biotechnology, Inc. a
South San Francisco-based genomics company announced today an agreement under which Eos will acquire a license to
MorphoSys' HuCAL (Human Combinatorial Antibody Library) technology for antibody generation.
Eos will apply the HuCAL technology in its pharmaceutical discovery programs for target validation and proteomics research.
In addition, Eos has an option to develop certain antibodies as therapeutics.
Under the agreement, Eos will pay technology license fees to MorphoSys as well as make milestone and royalty payments on
any antibody therapeutics. No financial details were disclosed.
``This deal illustrates again the importance of HuCAL in target and drug discovery, and is another successful step in our
commercialization of the technology as a tool for pharmaceutical research,'' said Simon Moroney, Chief Executive Officer,
MorphoSys AG.
``HuCAL is the ideal fit for our research engine,'' said David Martin, President and Chief Executive Officer of Eos. ``We
expect the HuCAL technology to greatly contribute to our highly parallel research process to rapidly validate our
genomics-derived targets. Our agreement with MorphoSys complements our existing technology collaborations with
Affymetrix, Inc. and Medarex, Inc. and is the latest step in Eos' aggressive technology partnering strategy in the
genomics-derived antibody field.''
MorphoSys develops and applies innovative technologies for the production of synthetic antibodies that accelerate drug
discovery and target characterisation. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library
(HuCAL) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing
and research collaborations with DuPont Pharmaceuticals (Wilmington, Delaware), Millennium Pharmaceuticals Inc.,
(Cambridge, Mass), Chiron Corporation (Emeryville, California) and GPC Biotech (Martinsried/ Munich). In December 1999
the Company signed a major R&D collaboration with Bayer AG (Leverkusen). The latest Cooperation was signed on May 30,
2000, with ProCHon Biotech (Israel).
Eos Biotechnology develops, applies and integrates a variety of high-throughput genomics, bioinformatics and biological
processes for the creation of novel therapeutic and diagnostic products. Eos technologies are being applied to rapidly and
cost-effectively build a pipeline of novel, medically important therapeutics and diagnostics in the areas of oncology, angiogenesis
and inflammation, with initial product development efforts focused in the area of therapeutic antibodies. Further information
about Eos and its programs is available at eosbiotech.com
SOURCE: MorphoSys AG and Eos Biotechnology, Inc. |
